Rational Integration of Polygenic Risk Scores (RIPS)
Rational Integration of Polygenic Risk Scores (RIPS)
批准号:
10589785
负责人:
Jing Hao
金额:
$95.53万
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
未结题
起止时间:
2022-03-10 至 2027-02-28
关键词:
AddressAdoptedAffectAgeAlgorithmsAreaAtherosclerosisCaringClinicalColorectal CancerComplexCosts and BenefitsDataData AnalysesDecision ModelingDevelopmentDiseaseDisparityEconomic ModelsEffectivenessEnvironmentEpidemiologyEquityFoundationsFundingGenomic medicineGenomicsGrowthHealthHeart DiseasesHereditary Breast and Ovarian Cancer SyndromeHereditary Nonpolyposis Colorectal NeoplasmsHyperlipidemiaInterventionInvestmentsMendelian disorderModelingOutcomePatient CarePatient-Focused OutcomesPerformancePopulationPopulation HeterogeneityPrevalencePreventive carePreventive measurePublishingResearchResearch PriorityReview LiteratureRiskRisk AssessmentRisk ReductionTechniquesTestingUncertaintyUnderrepresented PopulationsUnderserved PopulationUnited States National Institutes of HealthWorkclinical outcome assessmentclinical riskcostcost effectivecost effectivenessdisorder riskeconomic impacteconomic valuegene therapygenetic testinghigh riskimprovedmalignant breast neoplasmnew technologynovelpolygenic risk scoreprecision medicineprogramsscreening
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
There has been extraordinary growth in new techniques to predict common, complex disease
based on polygenic risk scores (PRS). Without an understanding grounded in evidence, it is
unlikely that the clinical use of PRS will propagate from highly specialized applications and
environments to become adopted more broadly and provide greater benefit to the US
population. Critical challenges include: 1) understanding the impact of clinical PRS for multiple
diseases on long-term patient outcomes, 2) identifying risk thresholds for return of results that
optimize patient outcomes and provide cost-effective care, 3) understanding how PRS
performance across diverse populations may affect existing disparities and subsequent patient
outcomes. We propose to address these challenges using decision analytic modeling and by
building on our extensive work in this area to create a novel framework capable of assessing
PRSs in the context of monogenic and clinical risks. We have already created clinical-economic
models to project lifetime clinical impact and cost-effectiveness for population-level genomic
screening with return of monogenic disease risks associated with three CDC Tier 1 conditions:
hereditary breast and ovarian cancer, Lynch syndrome, and familial hyperlipidemia. As part of
this proposal, titled Rational Integration of Polygenic Risk Scores (RIPS), we will create models
to assess the clinical outcomes and economic value of population screening using PRS in real-
world settings and applied to large and diverse populations. The Aims of the proposal include
1) to evaluate published and real-world evidence on the clinical value of adding PRS to inform
comprehensive genomic risk assessment; 2) to understand the impact of PRS performance
and return risk thresholds on incremental clinical benefit and cost effectiveness for breast
cancer, atherosclerotic cardiovascular disease, and colorectal cancer, and 3) to develop
research priorities for the equitable development and implementation of PRS across
underserved and underrepresented populations.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Rational Integration of Polygenic Risk Scores (RIPS)
-
批准号:10366293
-
项目类别:
-
资助金额:$99.92万
-
财政年份:2022
-
负责人:Jing Hao
-
依托单位:
Rational Integration of clinical SEquencing (RISE)
-
批准号:9768511
-
项目类别:
-
资助金额:$71.01万
-
财政年份:2017
-
负责人:Jing Hao
-
依托单位:
Rational Integration of clinical SEquencing (RISE)
-
批准号:9980443
-
项目类别:
-
资助金额:$70.98万
-
财政年份:2017
-
负责人:Jing Hao
-
依托单位:
海外基金